Hansoh Pharmaceutical Group stock (KYG4232C1087): Advances 1.2% in Hong Kong
Published on 05/12/2026 at 08:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hansoh Pharmaceutical Group stock advanced 1.2% in Hong Kong trading, closing 17% short of its 52-week high of HK$44.22 reached on January 15, 2026, with trading volume at 11.2 million shares, moomoo as of recent session.
As of: 12.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Hansoh Pharmaceutical Group Company Limited
- Sector/industry: Biotechnology / Pharmaceuticals
- Headquarters/country: China
- Core markets: China, global partnerships
- Key revenue drivers: Oncology drugs, innovative therapies
- Home exchange/listing venue: Hong Kong Stock Exchange (3692.HK)
- Trading currency: HKD
Official source
For first-hand information on Hansoh Pharmaceutical Group, visit the company’s official website.
Go to the official websiteHansoh Pharmaceutical Group: core business model
Hansoh Pharmaceutical Group focuses on research, development, manufacturing, and sales of innovative pharmaceuticals, with a strong emphasis on oncology, anti-infectives, and central nervous system disorders. The company operates primarily in China but pursues global partnerships for drug commercialization. Its pipeline includes small molecule drugs and biologics targeting unmet medical needs.
Hansoh employs an integrated model from discovery to market, leveraging its R&D centers in Shanghai and Suzhou. The firm has advanced multiple candidates into clinical trials, supported by collaborations with international players like Bristol-Myers Squibb in related pharma deals, highlighting sector momentum.
Main revenue and product drivers for Hansoh Pharmaceutical Group
Key products include oncology therapies such as HS-20093, a B7-H3 targeting antibody-drug conjugate in clinical development. Revenue stems mainly from commercialized drugs in China, with oncology contributing significantly. Partnerships, like past ties noted in industry reports, bolster pipeline value.
In 2023, Hansoh collaborated with global firms on cancer drugs, per Reuters May 11, 2026, reflecting active deal-making in Chinese biopharma. The company's presence in ETFs like Global X Aging Population (2.06% weighting as of recent holdings list, StockAnalysis latest) underscores investor interest.
Industry trends and competitive position
China's biopharma sector grows rapidly, driven by policy support for innovation and aging population needs. Hansoh competes with peers like Hengrui Pharma, which recently inked a USD950M deal with BMS for oncology programs, per AAStocks recent. Hansoh's focus on precision oncology positions it well amid global demand for targeted therapies relevant to US investors via ADR exposure or sector ETFs.
Why Hansoh Pharmaceutical Group matters for US investors
Hansoh offers US investors access to China's booming biotech market through its Hong Kong listing (3692.HK), included in aging-focused ETFs traded in the US. With partnerships echoing major deals like GSK's China expansions, it provides diversified exposure to innovative drugs potentially impacting global pharma supply chains.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
Hansoh Pharmaceutical Group continues to show trading momentum with a recent 1.2% gain in Hong Kong, supported by its oncology pipeline and sector partnerships. While below its yearly high, inclusion in US-accessible ETFs highlights potential. Investors monitor clinical progress and China market dynamics for future developments.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
